An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

Phase 1/2 Completed 23 enrolled Kyowa Kirin, Inc. Kyowa Hakko Kirin Pharma, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH).

Timeline

Start: 2012-02
Primary completion: 2013-09
Completion: 2014-06

Publications

Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. J Clin Endocrinol Metab. 2015 Jul;100(7):2565-73. doi: 10.1210/jc.2015-1551. Epub 2015 Apr 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Burosumab	Monoclonal antibody	0.05 mg/kg	Subcutaneous
Subject	Burosumab	Monoclonal antibody	0.1 mg/kg	Subcutaneous
Subject	Burosumab	Monoclonal antibody	0.3 mg/kg	Subcutaneous
Subject	Burosumab	Monoclonal antibody	0.6 mg/kg	Subcutaneous

An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

Summary

Timeline

Publications

Drugs

Indications